Amivantamab

Therapeutic indications

Amivantamab is indicated for:

Advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR)

Population group: both men and women, only adults (18 years old or older)

Amivantamab as monotherapy is indicated for treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, after failure of platinum-based therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines